Collexis Announces Market Leader Position in Scientific Grant Analysis.

Over $20 Billion in Scientific Funding Now Analyzed with Collexis

COLUMBIA, S.C. -- Collexis Holdings Inc. (OTCBB: CLXS), a leading developer of semantic search and knowledge discovery software, announced today that they are becoming the global leader in grant analysis and grant management tools in the sciences. With the recent launch of the National Institutes of Health (NIH) Categorization project, and the ongoing projects with leading private research funders, Collexis is analyzing over $20B in grant funds annually in the life sciences alone. Collexis expects their penetration within the grant management business segment to significantly grow in 2009.

"The largest public and private funders of biomedical research use Collexis to analyze their grant content," said Bill Kirkland, CEO of Collexis. "The largest public funder is our NIH project for disease categorization, and the largest private funder is our project for Wellcome Trust in the United Kingdom. We have similar projects with smaller funding organizations and we are seeing increased interest from research funders outside of the health sciences. This really puts us in the leadership position in the workflow and analysis of the scientific grant management process."

"This position is a great compliment to our leadership in Biomedical Expertise Profiling," said Dr. Christian Herzog, general manager for Collexis science, technical, and medical business. "We are now releasing products that intersect our knowledge of scientists with grant and literature sources - so we can automatically recommend the top global or regional reviewers for grants and journal manuscripts."

The recently launched Collexis Reviewer Finder is the first product version of Collexis tools that leading research institutions use to assign reviewers to grants. The system has 1.8 Million Expert profiles pre-loaded and automatically identifies co-author and institutional conflicts of interest. The Collexis Reviewer Finder system is being deployed selectively within the NIH, several large publishing partners, and other grant-funding agencies. The system also utilizes Collexis Expertise Profiles which are enterprise solutions for Johns Hopkins, Mayo Clinic, the NIH, and over 25 other leading academic medical institutions worldwide.

About Collexis Holdings, Inc.

Collexis Holdings, Inc., a leading developer of high definition search and knowledge discovery software is headquartered in Columbia, South Carolina (USA) with major operations in Cincinnati, Ohio, Geldermalsen, the Netherlands and Cologne, Germany. Collexis now offers the world's first pre-populated scientific social network for life science researchers, www.biomedexperts.com. Collexis' proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, Websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis' current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; Dana-Farber Cancer Institute, the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, visit www.collexis.com.

Disclaimer: National Institutes of Health (NIH) is not considered a supporter or partner of Collexis. Reference to NIH in the above shall not be construed as a Government endorsement nor does it obligate NIH to a position on or about the Collexis Software.

Forward-Looking Statements

Some of the statements made in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and include known and unknown risks, uncertainties and other factors, many of which the company is unable to predict or control, that may cause the company's actual results or performance to differ materially from any future results or performance expressed or implied by such forward-looking statements. These statements involve risks and uncertainties, including risks and uncertainties associated with the company's statements about the market acceptance of the company's Reviewer Finder product and its technology and related applications for the grant management process. These risks and uncertainties are in addition to other factors detailed from time to time in the company's filings with the SEC, including the section entitled "Risk Factors" in its transition report on Form 10-KSB for the period ended June 30, 2008, as amended. The company cautions investors that any forward-looking statements made by the company are not necessarily indicative of future performance. The company is not responsible for updating the information contained in this press release beyond the published date, or for changes made to this document by wire services or Internet services.